MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)(COMPLETED)

• Pain Relief at 2 Hours After Treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
  Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment
• Time to Relief Within 2 Hours After Treatment [ Time Frame: within 2 hours after treatment ] [ Designated as safety issue: No ]
  Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg).

• Pain relief at 2 hours after treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
• Time to relief within 2 hours after treatment [ Time Frame: within 2 hours after treatment ] [ Designated as safety issue: No ]

• Pain Free at 2 Hours After Treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
  Participants pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).
• Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
  Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest).
• Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
  Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment.
• Participants Who Used Escape Medication 2 Hours After the Treatment Dose [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
  Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication.
• Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1]) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence

• Pain free at 2 hours after treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
• No functional disability at 2 hours after treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
• Presence or absence of associated symptoms (photophobia, phonophobia, nausea, and vomiting) at 2 hours after treatment [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
• Patients who used escape medication 2 hours after the treatment dose [ Time Frame: 2 hours after treatment ] [ Designated as safety issue: No ]
• Duration of relief (Time to recurrence from the time of first recorded pain relief [grade = 0 or 1]) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.

• Drug: rizatriptan benzoate (MK0462)
  single dose 5 mg rizatriptan p.o.
  Other Name: MK0462
• Drug: Comparator: sumatriptan
  single dose 50 mg sumatriptan p.o.
• Drug: Comparator: Placebo
  Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally

• Experimental: 1
  Rizatriptan
  Intervention: Drug: rizatriptan benzoate (MK0462)
• Experimental: 2
  Sumatriptan
  Intervention: Drug: Comparator: sumatriptan
• Placebo Comparator: 3
  Placebo
  Intervention: Drug: Comparator: Placebo

Inclusion Criteria:

• Participant had at least a 6-month history of migraine, with or without aura
• Participant was male, or if female, must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions
• Participant was judged to be in good health, apart from migraine

Exclusion Criteria:

• Participant was Pregnant or a nursing mother
• Participant had a history or current evidence of drug or alcohol abuse
• Participant had a history or clinical evidence of cardiovascular disease
• Participant had a clinically significant Electrocardiography (ECG) abnormality
• Participant had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening
• Participant had received treatment with an investigational device or compound within 30 days of the study
• Participant typically suffered from less then 1 or more than 8 attacks of migraine per month
• Participant had difficulty in distinguishing his/her migraine attacks from tension or interval headaches
• Participant was currently taking monoamine oxidase inhibitors, methysergide or lithium